Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Cisplatin, Carboplatin and Durvalumab Treatment for Patients with Intermediate and High-Risk Oropharyngeal Cancer

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial focuses on oropharyngeal cancer, which is a type of cancer that affects the middle part of the throat, including the base of the tongue and tonsils. The study aims to compare different treatment approaches to improve survival rates in patients with intermediate and high-risk forms of this disease.

The treatment combines several medications given through intravenous infusion. These include cisplatin and carboplatin, which are chemotherapy drugs that help fight cancer cells, along with durvalumab, which is a type of medication that helps the body's immune system detect and fight cancer cells. These medications will be given together with radiation therapy, which uses high-energy rays to target cancer cells.

The study will monitor how well patients respond to the treatment combinations by tracking their overall health, quality of life, and ability to swallow. The treatment schedule includes regular visits to receive the medications and check-ups to monitor the patient's progress. Throughout the study, doctors will carefully watch for and manage any side effects that may occur from the treatment.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial evaluation

    Your eligibility will be confirmed through medical tests including blood work to check kidney function, liver function, and blood cell counts

    A physical examination will be performed to assess your overall health status and ECOG performance status (a measure of your ability to perform daily activities)

  2. Step 2

    Treatment assignment

    You will be assigned to one of the treatment groups for oropharyngeal cancer (cancer affecting the throat area)

    Your specific treatment plan will be determined based on your cancer characteristics and risk factors

  3. Step 3

    Treatment administration

    You will receive a combination of treatments that may include:

    Chemotherapy medications (cisplatin or carboplatin) given through an intravenous line

    Durvalumab (an immunotherapy medication) given through an intravenous line

    Radiotherapy will be administered alongside these medications

  4. Step 4

    Monitoring during treatment

    Regular assessments will track any side effects using standardized criteria

    Blood tests will continue to monitor your kidney function, liver function, and blood counts

    Your ability to swallow will be evaluated using specific assessment tools

  5. Step 5

    Follow-up assessments

    Quality of life assessments using questionnaires at specified intervals

    Evaluation of swallowing function at 24 months after treatment starts

    Regular check-ups to monitor your recovery and cancer status

    Assessment of any late side effects up to 2 years after treatment

Who can join the trial?

14 criteria

  • Age between 18 and 70 years
  • Diagnosed with oropharyngeal squamous cell carcinoma (cancer in the throat area, specifically in the base of tongue, tonsil, or uvula)
  • Must be recommended for treatment with combined chemotherapy and radiation therapy by a team of medical specialists
  • No other cancers in the past 5 years (except for non-melanoma skin cancer and certain cervical conditions)
  • Body weight more than 30 kg
  • Good overall physical condition (able to carry out all normal activities)
  • Expected survival of at least 3 months
  • Normal kidney function
  • Healthy blood cell counts
  • Normal liver function
  • Normal blood clotting function
  • For women who can become pregnant: must have either confirmation of post-menopausal status or a negative pregnancy test
  • Must provide written informed consent to participate in the trial
  • Must be willing to follow the study protocol, including attending all scheduled visits and examinations

Who cannot join the trial?

13 criteria

  • Age below 18 years or above 65 years
  • Previous chemotherapy (drug treatment) for head and neck cancer
  • Previous radiotherapy (radiation treatment) to the head and neck area
  • Previous surgery for oropharyngeal cancer
  • Presence of distant metastases (cancer spread to other parts of body)
  • Inability to give informed consent
  • Pregnancy or breastfeeding
  • Active serious infection including HIV (human immunodeficiency virus)
  • Serious heart or lung conditions that could interfere with treatment
  • Other active cancers in the past 5 years (except successfully treated non-melanoma skin cancer)
  • Mental health conditions that could affect participation in the study
  • Drug or alcohol dependency
  • Participation in other clinical trials within 30 days
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Based on the provided trial data, this appears to be a comparative study of treatment regimens for oropharyngeal cancer, but specific medications are not listed in the source data. Without explicit information about the medications or therapies involved, I cannot provide a detailed list of treatments and their descriptions. The trial appears to focus on comparing different treatment approaches for intermediate and high-risk oropharyngeal cancer, with an emphasis on survival outcomes, quality of life, toxicity, and swallowing function, but the specific interventions are not detailed in the provided data. If you would like me to list and describe the medications involved in this trial, please provide additional data containing information about the specific treatments being studied.

What is already known about the treatment

Since no specific medications are mentioned in the provided trial data, I cannot create medication descriptions in the requested format. The trial data only shows that this is a Phase III randomized controlled trial for oropharyngeal cancer treatments, but does not specify which medications are being tested or compared. To provide accurate medication descriptions, I would need information about the specific drugs or therapeutic agents being used in the CompARE trial. If you could provide the names of the medications being studied in this trial, I would be happy to create descriptions following the requested format: Medication Name – description

Investigated diseases

Oropharyngeal Cancer - A cancer that develops in the oropharynx, which is the middle part of the throat behind the mouth, including the base of the tongue, tonsils, and surrounding tissues. The disease typically begins in the squamous cells that line the throat and can spread to nearby lymph nodes. It may cause difficulty swallowing, persistent sore throat, and changes in voice quality. The condition can affect speech and swallowing functions as it progresses. Oropharyngeal cancer may develop gradually, often starting with changes in the cells of the throat tissue.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-516108-41-00Protocol codeRG_14-093Estimated enrolment785 patientsSponsorThe University Of Birmingham

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).